Creative Planning
BBOT

Creative Planning’s BridgeBio Oncology BBOT Stock Holding History

Creative Planning’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200,000
Closed -$2.12M – 4034
2025
Q2 		$2.12M Buy
+200,000
New +$2.16M ﹤0.01% 1266

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Creative Planning's BBOT Position: Q3 2025 in Review

Creative Planning sold out of BridgeBio Oncology (BBOT) in Q3 2025, closing a stake of 200,000 shares — an estimated $2.12M sold.

Creative Planning first reported a position in BBOT in Q2 2025 and held it in 1 quarter. The position peaked at $2.12M in Q2 2025. 42 funds tracked by Wall St. Rank hold BBOT as of Q3 2025.

  • Creative Planning reported no remaining BridgeBio Oncology position as of Q3 2025 after selling out during the quarter.
  • Creative Planning sold 200,000 BridgeBio Oncology shares in Q3 2025, an estimated $2.12M.
  • Creative Planning first reported a position in BridgeBio Oncology in Q2 2025 and held it in 1 quarter.
  • Creative Planning's BridgeBio Oncology position peaked at $2.12M in Q2 2025.
  • 42 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q3 2025.

Based on Creative Planning's 13F filing for Q3 2025, filed 14 Nov 2025.